Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1812
Cipriano L., Di Lillo A., Brosio F., Meloni P., Gioia S., Berta S., Pacifici E., Anceschi M. M.
Dipartimento di Scienze Ginecologiche, Perinatologia e Puericultura, Università degli Studi di Roma «La Sapienza», Roma
Aim. The aim of this paper is to study the efficacy of calcic nadroeparin, a low molecular weight heparin, for the prevention of venous thrombotic events occurring after cesarean section.
Methods. Between January 1 2001, to July 1 2002, a total of 66 patients who underwent a cesarean section, received calcic nadroeparin.
Hematological parameters were measured pre
operatively and on postoperative day 3.
Results. Of the 66 patients, 44 (67%) received 0.3 UI/ml calcic nadroeparin and 22 (33%), 0.4 UI/ml. The first dose of drug was administered in 34 (52%) patients intraoperatively, in 20 (30%) 4 hours, in 2 (3%) 8 hours and in 10 (15%) 12 hours postoperatively. The drug was given subcutaneously once daily for 5 or 8 days postoperatively. No significative variations of pre- and postoperative hematological parameters (PLT count, APTT, PT) were observed. No deep vein thrombosis, pulmonary embolism or infective complications occurred in any patients. All study patients were contactable at 2 and 6 weeks after cesarean section, and no thromboembolic complication was observed.
Conclusions. Deep vein thrombosis and pulmonary embolism are significant cause of post-operative morbidity and mortality in obstetric patients. Our study showed the importance of low-molecular-weight heparin (nadroeparin) in the prevention of thromboembolic events after cesarean section.